Open Label Extension Study of Brentuximab Vedotin in Early dcSSc

Recruiting now · Phase 2

Conditions studied: Diffuse Cutaneous Systemic Sclerosis

In brief

The purpose of this study is to assess safety and efficacy of Brentuximab vedotin, a CD30-directed antibody-drug conjugate, in patients with active diffuse cutaneous systemic sclerosis (dcSSc) who relapsed after discontinuation of Brentuximab vedotin.

Key facts

Study ID

NCT05149768

Run by

London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's

People needed

11

Starts

2024-02-14

Expected to finish

2026-07-01

Last updated by the study team

2024-11-18

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients with diffuse cutaneous systemic sclerosis enrolled in the Phase II Adcetris study (BV201708) at St. Joseph's Health centre, aged 18 years or older, and:
• Worsening mRSS of ≥ 4 points as compared to mRSS score at the end of treatment visit (week 48) in the initial study (BV201708).
• Able to give informed consent.

You may not qualify if…

• Poor pulmonary function (FVC<40% and/or DLCO<30%).
• Pregnancy, breast feeding or child bearing potential without practicing highly effective contraception (and partners for men in the study).
• Clinically significant pulmonary hypertension requiring drug therapy.
• Clinically significant cardiac disease.
• Chronic or ongoing active infectious disease requiring systemic treatment.
• Seropositivity for human immunodeficiency virus (HIV).
• Active tuberculosis (TB) infection.
• Active viral infection with viral replication of hepatitis B or C virus.
• Significant concurrent, uncontrolled medical condition including, but not limited to, renal, hepatic, pancreatic, hematological, gastrointestinal, endocrine, pulmonary, neurological, cerebral or psychiatric disease; and cancer.
• Peripheral neuropathy at screening Grade 2 or higher.
• Known or suspected hypersensitivity to components of the treatment
• Patients known or suspected of not being able to comply with a study protocol (e.g. due to alcoholism, drug dependency or psychological disorder)
• Any of the following laboratory abnormalities at screening:
• Absolute neutrophils count <2.0 x 109/L
• Hemoglobin <85 g/L
• Platelet count < 100 x 109/L
• AST/SGOT or ALT/SGPT >2.0 UNL
• Participation in another clinical trial within six weeks before randomization in this study, with the exception of continuation from the initial study BV201708.
• Use of rituximab within the previous 4 months.
• Immunization with a live/ attenuated vaccine less than 4 weeks prior to the baseline visit.
• Current or history of progressive multifocal leukoencephalopathy (PML).

Where it is running

• Rheumatology Clinic, St. Joseph's Health Care — London, Ontario, Canada (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.